Haemonetics Corporation (HAE)

Market Cap	4.27B
Revenue (ttm)	1.36B
Net Income (ttm)	123.81M
Shares Out	50.22M
EPS (ttm)	2.41
PE Ratio	35.24
Forward PE	17.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	524,437
Open	84.75
Previous Close	84.83
Day's Range	83.32 - 85.33
52-Week Range	70.25 - 97.97
Beta	0.32
Analysts	Strong Buy
Price Target	107.88 (+27.04%)
Earnings Date	Nov 7, 2024

About HAE

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provi...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 9, 1991
• Employees: 3,657
• Stock Exchange: NYSE
• Ticker Symbol: HAE
• Website: https://www.haemonetics.com

Financial Performance

In 2023, Haemonetics's revenue was $1.31 billion, an increase of 12.01% compared to the previous year's $1.17 billion. Earnings were $117.56 million, an increase of 1.87%.

Analyst Forecast

According to 8 analysts, the average rating for HAE stock is "Strong Buy." The 12-month stock price forecast is $107.88, which is an increase of 27.04% from the latest price.

Price Target

$107.88

(27.04% upside)

Analyst Consensus: Strong Buy